Omecamtiv Mecarbil MR is a small molecule commercialized by Cytokinetics, with a leading Pre-Registration program in Systolic Heart Failure. According to Globaldata, it is involved in 22 clinical trials, of which 21 were completed, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Omecamtiv Mecarbil MR’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Omecamtiv Mecarbil MR is expected to reach an annual total of $662 mn by 2032 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Omecamtiv Mecarbil MR Overview

Omecamtiv mecarbil (CK-1827452, AMG-423) is under development for the treatment of heart failure and heart failure with reduced ejection fraction (systolic heart failure). It is administered by intravenous as form of a solution and oral route as a form of modified release tablet. Omecamtiv mecarbil is a small-molecule, direct activator of cardiac myosin. It is a modified release formulation and is a new molecular entity.

The drug candidate was also under development for the treatment of ischemic cardiomyopathy, left ventricular systolic dysfunction hospitalized for acute heart failure and angina.

Cytokinetics Overview

Cytokinetics is a biopharmaceutical company with a focus on the discovery, development, and commercialization of muscle activators and muscle inhibitors as potential treatments for debilitating diseases wherein muscle performance is affected. The company develops small molecule drug candidates designed to affect muscle function and contractility. Cytokinetics is developing aficamten, a next-generation cardiac myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM). It is also developing reldesemtiv, a fast skeletal muscle troponin activator, for the treatment of ALS patients. The company has licensing and collaboration agreements with Amgen, Ji Xing, and Astellas for advancing its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.

The company reported revenues of (US Dollars) US$70.4 million for the fiscal year ended December 2021 (FY2021), an increase of 26.2% over FY2020. The operating loss of the company was US$186.3 million in FY2021, compared to an operating loss of US$93.9 million in FY2020. The net loss of the company was US$215.3 million in FY2021, compared to a net loss of US$127.3 million in FY2020. The company reported revenues of US$2.5 million for the third quarter ended September 2022, a decrease of 97.2% over the previous quarter.

For a complete picture of Omecamtiv Mecarbil MR’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.